Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.61 |
| ▸ | FPR2 | P25090 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374657 | 1.00 | SCN9A (0.61) | SCN9AFPR2TSHRKMT2ACTSS | |
| SCHEMBL9545318 | 0.90 | CTSK (0.54) | SCN9AFPR2TSHRCTSSCTSL | |
| SCHEMBL29922866 | 0.89 | FPR2 (0.64) | SCN9AFPR2CTSSCTSLCTSB | |
| SCHEMBL2684054 | 0.88 | FPR2 (0.57) | SCN9AFPR2KMT2ACTSSCTSL | |
| SCHEMBL2684050 | 0.88 | FPR2 (0.57) | SCN9AFPR2KMT2ACTSSCTSL | |
| SCHEMBL27723881 | 0.88 | FPR2 (0.57) | SCN9AFPR2KMT2ACTSSCTSL | |
| SCHEMBL9544272 | 0.86 | CTSK (0.52) | SCN9ATSHRCTSLCTSBCTSK | |
| SCHEMBL9544268 | 0.86 | CTSK (0.52) | SCN9ATSHRCTSLCTSBCTSK | |
| SCHEMBL9542635 | 0.85 | CTSL (0.64) | CTSSCTSLCTSKACE | |
| SCHEMBL2685669 | 0.85 | SCN9A (0.51) | SCN9AFPR2KMT2ACTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | SCN9A 3807/4885FPR2 1125/4885TSHR 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.